fbpx
Connect with us

MARKETS

ASG Pharma (“ASG”), A Subsidiary Of Aphria Inc (OTCMKTS:APHQF),Obtains Its First Import License For Cannabis

Published

on

ASG Pharma (“ASG”), a subsidiary of Aphria Inc (OTCMKTS:APHQF), will be the first party to benefit from the first import license for medical cannabis that was recently issued out by the Malta Medicines Authority (“MMA”).

Obtaining the license and its associated benefits

One of the officials working with the company outlined that the license will enable ASG import medical cannabis for research and analytical testing. According to him, ASG is on its way to becoming the cornerstone in testing, research and development of medical cannabis across Europe despite the stiff competition being experienced at the moment.

The Head of International Development at Aphria Antonio Costanzo opined, “Malta’s legislative and regulatory standards are extremely rigorous, and we are pleased and proud that the MMA has awarded this import license to ASG. ASG adheres to the highest international standards and we look forward to upholding this high bar as a leading European hub for medical cannabis.”

An outlook into the future

The processing and manufacturing capabilities of ASG Pharma will soon be upgraded and that will be in an effort to increase its capability to process, extract, and package and label cannabis derivative pharmaceutical-grade medical and cannabis products.

The CEO of Aphria Vic Neufeld while addressing a number of news reporters said that their EU GMP-certified lab in Malta will present a gateway to medical cannabis markets across Europe and it is also worth mentioning that it is currently the top European center for R&D and testing.

He went a step further to outline that as a company they were pursuing the bets attractive strategic opportunities for medical cannabis not only in Europe but globally.

The passage of Bill C-45

The company through its spokesperson has outlined that it is indeed happy having witnessed the passage of Bill C-45 through the Senate. It is a new dawn for the company since it will now be able to provide safe and legal recreational cannabis in Canada.

And this is happening at a time when business dynamics tend to be shifting quite fast. It is easy to tell that the company is with the passage of time making progressive steps towards establishing itself as the preeminent leader in the global cannabis sector.

MARKETS

CV Sciences Inc (OTCMKTS:CVSI) Navigates Market Storms

Published

on

Any company that faces the campaign of short sellers experiences hard times; especially the shareholders. In the recent months, CV Sciences Inc (OTCMKTS:CVSI) had a rough battle with the investors which badly bruised the share price. In an Aug. 30, 2018 press statement, the company gave an update to shareholders regarding the situation.

In the update, CV Sciences acknowledges the “malicious” intent of the short sellers. The company CEO, Joseph Dowling further explains that they are victims of “campaigns run by short sellers in order to depress our stock price, so they could make financial windfalls.”

Manipulations

The CEO further details that: “We are also aware that at least one such group has boasted on social media platforms about its financial returns since their release of misleading information regarding the Company’s patent prosecution and drug development efforts.”

In rebuttal, the CEO affirms that the company presents strong financial numbers and that this will go on in future. He adds that there is nothing different with the business model since it is solid. Joseph speaks out so strongly about the “manipulations” and offers his sympathy for the shareholders.

“We will continue to do everything in our control to bring this activity to a halt. In the months ahead, we look forward to reporting our operating results in this fast-growing industry and providing updates on our drug development efforts,” he says.

A product milestone for CV Sciences Inc (OTCMKTS:CVSI)

The run in with the short sellers did not dampen the company’s spirits. In under two weeks, the company announced a great milestone for one of its products. The PlusCBD Oil™ Gold Formula product line acquired the Generally Recognized as Safe (GRAS) status. The status implies successful performance on the safety front. Further, the GRAS status implies the U.S. Food and Drug Administration (FDA) approves of the production and supply of PlusCBD Oil™.

Such a status is important to product sales and consumer confidence in the company. Concurring with the assessment, the CEO says:

“We are committed to building consumer confidence and trust in the safety and quality of our products, supported by scientific evidence.

Continue Reading

BUSINESS

Tilray (TLRY) Joins Cannabis Sector’s Pause, Which Is Good News For People Who Missed Its July IPO

Published

on

With the high-flying cannabis sector taking a pause, now is the time for investors to reassess their positions.

A good place to start would be by taking a moment to examine who is guiding cannabis-focused companies. In other words, who is it that is forming a company’s reputation.

Take, for example, high-flying Tilray, Inc. (TLRY). It’s a pioneer in medical cannabis research, cultivation, processing, and distribution. Now it is rapidly staking a strong place in Canada’s soon-to-be legal adult marijuana market.

Looking beyond its world-class research teams, investors will discover Tilray has one of the sector’s most prestigious board of directors.

Tilray’s board includes Rebekah Doop, who is a principal at Google. Then there’s Scotty Greenwood, who was chief of staff sat the U.S. Embassy in Canada, and is now the CEO of the Canadian American Business Council.

Of course, the board itself is not solely responsible for the 400 percent run up since Tilray’s July IPO. Still, it should comfort investors to know Tilray is in such good hands.

Doop and Greenwood are joined on the board by other corporate heavyweights, such as Christine St. Claire, who was a principal and lead audit partner at KPMG; Michael Auerbach, a risk expert who has held senior positions at the Center for American Progress and The Century Foundation, where he concentrated on issues related to U.S. Foreign Policy, National Security, and Conflict Resolution.

Rapid Expansion Into Legalized Pot

Based in British Columbia, Canada, Tilray is global concern. It is the only GMP-certified medical cannabis producer to supply cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments, and researchers in 11 countries on five continents.

It’s also perfectly positioned in the heart of Canada’s legalized cannabis industry.

The Prince Edward Island Cannabis Management Corporation recently selected a Tilray subsidiary to supply its adult-use cannabis.

The purchase order will allow its wholly owned affiliate, The High Park Company, to supply PEI’s four cannabis stores and online channels with cannabis products. It’s all in anticipation of the launch of the adult-use market on October 17, 2018.

In all, Tilray has signed agreements to supply adult-use cannabis to consumers in seven Canadian provinces and territories, including British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, the Yukon territory, and the Northwest Territories

Its subsidiary, High Park, is Toronto-based, and is led by a team with deep experience in cannabis and global consumer brands.

Tilray established High Park in order to develop, sell, and distribute a broad-based portfolio of adult-use cannabis brands and products. Its portfolio is uniquely crafted and grown by master horticulturists dedicated to sustainable growing practices.

Tilray’s shares were downgraded Northland Capital, which gave “complex valuations” as the basis of its esoteric reasoning. Tilray’s share price shed nearly 11 percent on the news.

But Tilray is a strong company.

It has a partnership to develop medical products with Sandoz Canada, a division of Novartis (NVS). Tilray also has a relationship with Privateer Holdings and marijuana information website Leafly, along with distribution deals with Shoppers Drug Mart, Pharmasave and various Canadian provinces.
It is perfectly posi

Continue Reading

MARKETS

PotNetwork Holdings Inc. (OTCMKTS:POTN) Firing On Products Sales Despite Stock Underperformance

Published

on

PotNetwork Holdings Inc. (OTCMKTS:POTN) has underperformed the industry, depicted by the stock shedding more than 60% in market value.  However, the poor run in the market cannot in any way be attributed’ to deteriorating business performance. The company appears to be firing on all cylinders more so on product sales.

$2 Million Record Sales

The company’s wholly owned subsidiary Diamond CBD Inc. is fresh from announcing revenues of over $2 million, which represents an 80% year-over-year growth. The increase also underscores a continued trend that has seen it reach record heights each quarter.

Diamond CBD record-breaking trend continued at the just concluded Las Vegas Champs Show that saw the company generate $300,000 worth of purchase orders.  At the event, the company was able to showcase its product line made up of Vape Additives, Liquid Gold Vape Juice and CBD Gummies among many more.

“Diamond CBD has a highly successful history of sales from these key trade shows.  Key among them are the CHAMPS Trade Shows which strive to provide the best trade show experience possible by matching exhibitors with buyers from throughout the world,” company in a statement.

PotNetwork Holdings attributes the stellar performance to the unit’s expansion drive that has seen it launch innovative product lines that continue to elicit strong demand in the market.  Innovative sales strategies, as well as market diversification, have also worked to the unit’s advantage in generating new sales.

In a bid to protect market share already accrued, PotNetwork Holdings has engaged the services of two national law firms that are to handle intellectual property and regulatory guidance.  The law firms should help the company explore trademarks essential for solidifying existing and forthcoming market positions.

Price Action

Despite the stellar performance on the business execution front, PotNetwork Holdings remains under pressure depicted by share price action. The stock is currently trading near a critical support level at the $0.20 level, below which it could drop further.  It remains to be seen if Diamond CBD achievements will help strengthen, investor sentiments in the stock thereby trigger a bounce back from the current lows.

Continue Reading
Advertisement
Advertisement
Advertisement






Trending Stories